Achieve consistent, long-term IOP control in cases of severe and complex glaucoma with the Molteno3® Glaucoma Drainage Device

Implanted in thousands of patients worldwide, the Molteno3® Glaucoma Drainage Device has been clinically validated to deliver consistent, long-term reduction in intraocular pressure (IOP) in cases of severe or complex glaucoma. It has also been shown to offer the benefit of improved practice efficiency.

One of the coolest things about the Molteno3® is its efficiency. It’s a true single quadrant surgery. There’s no muscle involvement and so you don’t have to worry about dissecting the muscles or using muscle hooks.”

A History of Innovation

Molteno3® is the culmination of more than 50 years of research and development. First introduced in 1966, the Molteno3® Glaucoma Drainage Device (GDD) reflects a history of extensive research into bleb formation and function – and is considered to be the gold standard in GDD technology.

1966

Prof. Anthony Molteno invents the world’s first glaucoma drainage device for human use.

1973

Introduction of the Molteno® second generation glaucoma drainage device.

1980

Prof. Anthony Molteno pioneers concept of delayed drainage (with Vicryl® Tie) to prevent post-op hypotony and to reduce bleb fibrosis.

1980

Introduction of the Molteno® double-plate glaucoma drainage device.

1990

Introduction of the Molteno® D1 glaucoma drainage device, featuring a pressure ridge designed to reduce hypotony.

2000

Launch of the Molteno3® third generation glaucoma drainage device (Molteno3® G-Series), featuring proprietary, patented Primary Drainage Area for staged bleb formation.

2012

Launch of the Molteno3® S-Series, which includes three models: Molteno3® SS (185mm2), Molteno3® SL (245mm2) and Molteno3® P1 Pediatric/Microophthalmic (80mm2).

The Molteno3® is designed to enhance surgical utility and optimize clinical outcomes

The novel design elements of the Molteno3® enable it to achieve the same clinical outcomes as larger plate alternatives via a shorter, simplified surgical procedure.1

1. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50.

At just 0.4mm, the Molteno3® is the slimmest plate on the market and slides easily between tissue planes and adjacent extraocular muscles. This simplifies the surgical procedure and reduces patient discomfort.

The Molteno3® features a smooth polypropylene plate that reduces the risk of bleb fibrosis; the Molteno3® has one of the lowest reported rates of bleb encapsulation.2

2. Hong C‑H, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: A systematic literature review and current controversies. Surv. Ophthalmol 2005; 50:48 – 60

The Molteno3® S‑Series is up to 15 minutes faster to implant than larger plate alternatives.3

3. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50.

Visit the Molteno3 website
Glaucoma-Molteno.com

References
1. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50.
2. Sun, PY et al. Diplopia in Medically and Surgically Treated Glaucoma Patients Ophthalmology. 2017 Feb; 124(2): 257 – 262.
3. Nour-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed glaucoma valve. Am J Ophthalmol 2003;136:1001 – 8.
4. Hong C‑H, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: A systematic literature review and current controversies. Surv. Ophthalmol 2005; 50:48 – 60
5. Molteno AC, Fucik M, Dempster AG, Bevin TH. Otago Glaucoma Surgery Outcome Study: factors controlling capsule ¬brosis around Molteno implants with histopathological correlation. Ophthalmology. 2003 Nov 30;110(11):2198 – 206)
6. Välimäki, J O et al. Molteno3 Implantation as Primary Glaucoma Surgery. J Ophthalmol. 2014; 2014167564.
7. Sheybani et al. Differences In Intraocular Pressure and Medication Usage Between The Baerveldt And Molteno Glaucoma Drainage Devices. 29th Annual Meeting of the (AGS), 2019
8. Molteno ACB, et al. Long-Term Results of Primary Trabeculectomies and Molteno Implants for Primary Open-Angle Glaucoma. 2011. Arch Ophthalmol; 129(11):1444 – 1450


Indications: The Molteno3® Glaucoma Drainage Device is indicated to reduce intraocular pressure in neovascular glaucoma and glaucoma where medical and conventional surgical treatments have not been successful, to control the progression of disease.

Contradictions: Patients with the following conditions may not be suitable candidates for the Molteno3® Glaucoma Drainage Device: 1. intraocular infection, 2. rheumatoid arthritis, scleritis and immune corneal melt syndromes, 3. Scleral Buckle.

Complications: Possible complications with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: choroidal detachment, retinal detachment, expulsive haemorrhage, pupillary block, lenticulo-ciliary block, shallowing and flattening of the anterior chamber, intraocular infection, diplopia, loss of central vision, hypotony and corneal endothelial damage.

Adverse events: Possible adverse events with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: corneal endothelial damage when the tube touches the corneal endothelium, breakdown of the tissues overlying the bleb, diplopia when the placement of the implant interferes with the action of the extraocular muscles, corneal decompensation, progression of lens opacities, cystoid macular oedema, retinal detachment and intraocular infection.

Precautions: Caution should be taken with supra-Tenon implantation; erosion of the conjunctiva is known to result from the raised edge of the oval pressure ridge (Molteno3® G‑Series).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More